Increasing PrEP With Trans Women in the Deep South
T'Cher, Take Charge: Increasing PrEP Awareness, Uptake and Adherence Through Health Care Empowerment and Addressing Social Determinants of Health Among Racially Diverse Trans Women in the Deep South
CrescentCare
200 participants
Jan 31, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this to address barriers and facilitators to PrEP uptake, and encourage adherence among trans women via a single arm stepped wedge clinical trial. The main question is to compare PrEP uptake and adherence outcomes among trans women in the T'Cher intervention to the delayed study arm.
Eligibility
Inclusion Criteria9
- Provision of signed and dated informed consent form
- Declaration of willingness to comply with all study procedures and availability during the study
- Age 18 years old or older
- Male sex designated at birth
- Identify as trans woman, woman or another gender identity not associated with being a man
- Desire to use or re-start PrEP
- HIV uninfected
- Speaks English or Spanish
- Live in the New Orleans metropolitan statistical area (which includes 8 parishes)
Exclusion Criteria5
- Confirmed HIV infection by rapid algorithm testing and/or laboratory testing (described above)
- Prior or current participation in the active arm of an HIV vaccine trial with evidence of vaccine-induced seropositivity
- Concurrent or planned enrollment in a research study that provides PrEP
- Unwilling to attend quarterly follow-up visits, which will include survey participation
- Has any other condition which, based on the opinion of the investigator, would preclude provision of informed consent; make participation in the project unsafe; complicate interpretation of outcome data; or otherwise interfere with achieving the project objectives
Interventions
Ecological momentary assessments to identify and address stressors related to social determinants of health (e.g., housing, substance use, mental health), and motivational interviewing to support participants' health care empowerment and progression along the PrEP continuum.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05689281